Thursday 7 October 2021

Short introduction to the Symposium

Non-clinical testing of human medicinal products: challenges and opportunities for regulatory acceptance of 3Rs
SONJA BEKEN - Coordinator non-clinical evaluators, senior GMP inspector FAMHP (Federal Agency for Medicines and Health Products) at FAGG, Brussels, BE

The relevance of animal models and alternatives in nonclinical safety testing and human risk assessment for pharmaceuticals
ROBER MADER, Senior Principal Scientist ROCHE Pharma Research and Early Development, ROCHE Innovation Center, Basle, CH

Human self-testing of experimental drugs? Vaccines in pandemic times
CHRISTA THÖNE-REINEKE-Professor and Head of Institute, Veterinary specialist in Laboratory Animal Science and Physiology, University of Berlin, Chair of the Scientific Committee for the Bf3R, Berlin, DE

Human-relevant models: the case of Alzheimer’s and Parkinson’s disease
LIESBETH AERTS-Senior Researcher Biomedical Sciences-Science Communicator KUL/VIB-Infopunt Proefdieronderzoek, BE

REGISTER ONLINE FROM SEPTEMBER
Friday 8 October 2021

Organ-on-chip
JANNY VAN DEN EYNDEN-VAN RAAY, Managing Director at hDMT, Organ-on-Chip Consortium, Eindhoven, NL

Species differences in the mechanism of action of drugs on the thyroid function
THOMAS STEGER-HARTMANN, Head of Investigational Toxicology, Bayer Pharmaceuticals, Berlin & Wuppertal, DE

Stem cells as source of human target cells
MUSTAPHA NAJIMI, Senior Research Associate at the Laboratory of Pediatric Hepatology & Cell Therapy at the UCL, Brussels, BE

Hope for in vitro alternatives in developmental and reproductive toxicology?
GIEL HENDRIKS – CEO Toxys, The Hague, NL

RE-Place: the central database for Replacement Methodology for which Expertise exists in Belgium
BIRGIT MERTENS, Senior Researcher Risk and Health Impact Assessment at Sciensano, Brussels, BE

REGISTER ONLINE FROM SEPTEMBER

www.IC-3Rs.org